Fenbendazole and Cancer: The Science, The Protocols, and What You Need to Know

In 2019, a retired businessman named Joe Tippens posted a blog entry claiming his terminal small-cell lung cancer had gone into complete remission. His protocol? Among other things, fenbendazole — a cheap, widely available veterinary dewormer. The internet exploded. Researchers took notice. And five years later, the scientific literature on fenbendazole and cancer has grown substantially.

What Is Fenbendazole?

Fenbendazole (FBZ) is a benzimidazole antiparasitic medication used in veterinary medicine for decades. It’s safe, inexpensive, and well-characterized. It’s also not FDA-approved for human cancer treatment. What makes it interesting to oncologists is its mechanism: fenbendazole acts on structures that cancer cells depend on more than healthy cells do.

How Fenbendazole May Fight Cancer: 4 Core Mechanisms

1. Microtubule Disruption — The Structural Attack

Fenbendazole binds to β-tubulin at the same site as colchicine, blocking the polymerization of tubulin into microtubules. Microtubules are essential for cell division. Cancer cells, which divide rapidly and continuously, are particularly vulnerable.

In a landmark 2018 study in Scientific Reports, Dogra et al. demonstrated that fenbendazole acted as a “moderate microtubule destabilizing agent” that killed cancer cells by modulating multiple cellular pathways simultaneously. Crucially, it showed activity against cell lines resistant to taxane-based chemotherapy [1].

2. Glucose Deprivation — The Metabolic Attack

Cancer cells consume glucose at an extraordinarily high rate — the Warburg effect. Fenbendazole reduces the expression of GLUT1 (the main glucose transporter) and inhibits hexokinase II (HKII), the first enzyme in the glycolytic cascade. It cuts off the cancer cell’s primary fuel supply.

3. p53 Activation — Turning On the “Guardian of the Genome”

The p53 protein monitors for DNA damage and either triggers repair or forces the cell to self-destruct. In cancer, p53 is frequently suppressed. Fenbendazole promotes p53 stabilization by suppressing its negative regulators Mdm2 and MdmX [2].

4. Anti-Angiogenic Effect — Cutting Off the Blood Supply

Tumors need new blood vessels to survive. Molecular docking studies have identified fenbendazole as a potential VEGFR-2 antagonist, and in vitro studies showed FBZ significantly reduced VEGFR-2 concentrations [3].

The Evidence Landscape

What the science confirms:

• Extensive preclinical data across NSCLC, SCLC, breast, colorectal, ovarian cancer, glioblastoma, and more
• Multiple peer-reviewed publications in Scientific Reports, Anticancer Research, IJMS

What the science does NOT confirm (yet):

• No completed randomized controlled clinical trials in humans
• No standardized dosing protocol validated in humans

The Joe Tippens Protocol (Original)

The Higher-Dose Approach (444mg)

Many practitioners now use the 444 mg dose daily (3 days on / 4 days off), arguing that the low bioavailability of FBZ requires higher doses to reach effective tissue concentrations.

The Bioavailability Problem

Fenbendazole’s biggest pharmacokinetic challenge is its very low oral bioavailability. Practical strategies:

• Take with fat — a fatty meal can meaningfully increase absorption
• Vitamin E Succinate — a fat-soluble companion
• Piperine (black pepper extract) — may enhance absorption

Safety: What You Need to Watch

Hepatotoxicity (liver injury): This is the primary documented risk. Published case reports describe Drug-Induced Liver Injury (DILI) in cancer patients self-administering fenbendazole [5], [6].

Monitor: ALT, AST, GGT, bilirubin — before starting, at 2 weeks, then monthly.